EuMentis Therapeutics’ CMO Randall Marshall to Present on its novel PDE10A inhibitor for Tourette Syndrome at TicCon24
May 29, 2024
EuMentis Therapeutics, Inc. announced today that the Company’s Chief Medical Officer, Randall Marshall, MD, will be presenting at the Tourette Association of America’s TIC-CON24 Research Symposium being held on May 31st in Dallas, Texas.
Download PDF